Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

Cassava Sciences' Alzheimer's drug simufilam failed its Phase 3 trial and the stock plummeted ~90%. See why I changed my ...

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Cassava Sciences’ ReThink-ALZ phase 3 study of simufilam in mild-to-moderate AD fails to meet co-primary endpoints: Austin, Texas Wednesday, November 27, 2024, 18:00 Hrs [IST] C ...

Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...

Cassava's stock plummets as its investigational Alzheimer's disease drug failed to show a significant reduction in cognitive or functional decline.

Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...

Inc. (NASDAQ: SAVA) witnessed a dramatic over 85% plunge in its stock price following the release of disappointing results ...

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate ...

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cassava ...

Cassava Sciences’ phase 3 Alzheimer’s disease trial has missed its co-primary endpoints. With the study also missing ...